DOCSLIB.ORG

To Study the Prevalence of Arrhythmias in Valvular Heart Disease and Their Correlation with Echocardiographic Variables

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
To Study the Prevalence of Arrhythmias in Valvular Heart Disease and Their Correlation with Echocardiographic Variables Original Article DOI: 10.7860/JCDR/2018/36767.12300 Internal Medicine To Study the Prevalence of Arrhythmias in Section Valvular Heart Disease and their Correlation with Echocardiographic Variables SANJA SAMEER BEHRA1, AVS ANIL KUMAR2, HARKIRAT SINGH3, K SATYANAND4 ABSTRACT Results: It was found that 122 (45.5%) patients had arrhythmias, Introduction: Valvular Heart Disease (VHD) is an important out of which Atrial Fibrillation (AF) contributed the most 100 cause of arrhythmia which may manifest as syncope or (37.3%), followed by Premature Ventricular Contraction (PVC) palpitations or may be asymptomatic. VHD is very common in in 22 (8.9%) patients. There were 19 (12.5%) of the 152 India and Rheumatic Heart Disease (RHD) contributes maximally asymptomatic patients who had arrhythmias. Patients of mitral to it. There are a substantial proportion of patients in whom valve disease with AF had a mean Mitral Valvular Area (MVA) of arrhythmias go undetected due to paucity of typical symptoms. 1.20±0.39 cm2, Mean-transmitral Gradient (MG) of 14.03±3.10 The patients with arrhythmias are highly prone to Cerebro mm of Hg. The mean Left Atrial (LA) diameter for all the VHD Vascular Accidents (CVA) due to thromboembolic phenomenon. (100 cases) with AF was 48.73±3.57 mm. The mean Left Hence, it is important to detect arrhythmias early so that timely Ventricular Internal Dimension in Diastolic (LVID D) and systolic preventive measures can be put in place. (LVID S) phase was evaluated for cases of Mitral Regurgitation (MR), Aortic Regurgitation (AR) and Aortic Stenosis (AS) for Aim: Establishing the overall prevalence of arrhythmias in all the arrhythmias and were found to be 48.74±6.25 mm and VHD, proportion of asymptomatic arrhythmias, the type of 36.69±5.18mm respectively. arrhythmias occurring in this population subset and the factors which increase the risk of occurrence of arrhythmias. Conclusion: There is significant proportion of patients with VHD having asymptomatic arrhythmias; hence 24- Materials and Methods: The study included 268 consecutive hour Holter monitoring should be used to detect these early. patients of VHD enrolled between July 2015 to Jun 2016. Echocardiographic variables like LA diameter, MG, MVA, LVID S Patients were evaluated with complete history and clinical and LVID D for arrhythmias. The critical point beyond which the examination along with relevant haematological and biochemical patient is more prone to get an arrhythmia as per our study was investigations, echocardiography and 24 hour ambulatory Holter when LA diameter >43 mm, MVA <1.7 cm2, MG >09 mm Hg, monitoring. For baseline comparison of patients, chi-square (χ2) LVID D >50 mm and LVID S >39 mm. Patients with multivalvular test was used for descriptive variables. Quantitative variables involvement are more prone for arrhythmia. were compared using the independent sample t-test. Keywords: Atrial fibrillation, Holter monitoring, Mitral stenosis, Rheumatic heart disease INTRODUCTION Additionally, it is used for the analysis of the type, duration, Valvular Heart Disease is an important cause of arrhythmia. In the severity, quantification and qualification of these arrhythmias in recent years, there has been a steady decline in the prevalence this population subset [6,7]. There are various echocardiographic of VHD and the resultant arrhythmias in western countries [1]. variables, which are also associated with risk of onset of However, the prevalence still remains high in developing as well arrhythmia. If we can detect the arrhythmia early or detect as in third world countries [2]. The patients with arrhythmias the parameters which are associated with increased risk of are highly prone to Cerebro Vascular Accidents (CVA) due to arrhythmias, preventive measures can be undertaken. thromboembolic phenomenon. Early intervention can prevent and The data on the prevalence of arrhythmias, particularly asymptomatic forestall these thromboembolic events particularly, primary and arrhythmias, type of arrhythmias and echocardiographic variables recurrent CVAs [3]. Prevention of these thromboembolic events in the subset of population of VHD in South western part of the requires that the patient receives anticoagulant therapy. The most country is scanty which prompted us to undertake this study. common arrhythmia in VHD is Atrial Fibrillation (AF). A study by Wipf JE et al., reported AF prevalence rate of 75% in Rheumatic MATERIALS AND METHODS Heart Disease (RHD) [4]. Study done by Diker E et al., in 1110 This cross-sectional observational study was conducted at a tertiary patients of rheumatic VHD reported a frequency of 39% for AF [5]. care teaching hospital over a period of one year from July 2015 to AF due to VHD, particularly mitral valve disease has a substantially June 2016. Prior clearance was taken from the institutional ethical higher risk for CVAs than with AF with non-valvular heart disease. committee. Informed written consent was taken from the patients. Also there is a greater CVA risk in patients with permanent AF than Consecutive patients of all functional classes as defined by the New in patients with paroxysmal AF and the risk of stroke is highest in York Heart Association (NYHA) were included (Total 280). Patients the year of onset of the arrhythmia [4]. with concurrent other heart diseases and patients below 18 years Arrhythmias can result in symptoms like palpitations and of age were excluded from the study. Coronary heart disease was syncope. But there are a substantial number of patients with excluded by ECG findings, echocardiography and wherever clinically VHD in whom arrhythmias may go undetected due to a paucity suspected stress Myocardial Perfusion Imaging (MPI) was done. of clinical symptoms and in whom Holter monitoring has proved Total six patients were suspected to have CAD and were excluded. to be invaluable tool in identifying any underlying arrhythmias. Two had dilated cardiomyopathy and were also excluded. Four 12 Journal of Clinical and Diagnostic Research, 2018, Nov, Vol-12(11): OC12-OC19 www.jcdr.net Sanja Sameer Behra et al., Prevalence of Arrhythmias in Valvular Heart Disease and Their Correlation with Echocardiographic Variables patients were lost to follow-up. Rest of the patients (total of 268) Arrhythmia were all included in the study [Table/Fig-1]. Total Present Absent ≤20 1 5 6 21-30 13 69 82 31-40 40 42 82 Age group 41-50 38 23 61 51-60 18 3 21 >60 12 4 16 Total 122 146 268 [Table/Fig-2]: Arrhythmia in different age groups. 43(16%), Aortic Regurgitation (AR) in 45 (17%) of patients (total isolated as well as in combination) [Table/Fig-3]. Overall involvement of mitral valve was 243 (90.6%) and aortic valve was 48 (18%). The pulmonary valve involvement {both stenosis (PS) and regurgitation (PR)} was 0.7% and that of tricuspid valve involvement {both stenosis (TS) and regurgitation (TR)} was 14 (5.2%). Our study showed the various valvular involvements in decreasing frequency as follows: MS in 98(36.5%) >MS+MR in 64 (24%) >MR in 48 (17.9%) > AS in 10 (3.73%) >AR in 10 (3.73%) >MS+MR+AS+AR in 9 (3.36%) > MS+MR+AS in 7(2.61%) >MR+TR >AS+AR >MR+AS >MR+AR > [Table/Fig-1]: Showing patient participation. MS+MR+TR [Table/Fig-3]. A detailed history was taken to find out any symptoms related to the AF Total (%), valvular lesions arrhythmias (unexplained syncope and palpitation that were non- Present (%) In whole cohort exertional), history of alcohol intake or medication that can provoke arrhythmias. They underwent detailed physical examination, routine AR 0 0.0 5 1.9 haemogram, biochemistry, Erythrocyte Sedimentation Rate (ESR), AS 0 0.0 10 3.7 C-Reactive Protein (CRP), chest radiography (X-Ray), thyroid BAV 0 0.0 5 1.9 profile and Electrocardiogram (ECG). All patients underwent an MS 31 42.5 73 27.2 echocardiography (iE33 PHILIPS serial no-4158990) to affirm the MR 11 25.6 43 16.0 presence of VHD, to study the various echocardiographic variables of Mitral Valve Area (MVA), Mitral Gradient (MG), Left Ventricular MVP 0 0.0 5 1.9 Internal Dimensions (LVID) and Left Atrial Diameter (LA dia) and PS 0 0.0 1 0.4 to ascertain the current cardiac status. Consequent to which the AS+AR 0 0.0 3 1.1 patient underwent 24 hour ambulatory Holter monitoring (Holter MR+MS 33 50.8 65 24.3 medilog FD 12 Holter recorder with serial no 92345 made by Schiller). MR+AR 0 0.0 2 0.7 The patients’ Holter recordings were reviewed in our OPD and documented and were advised to promptly report if they developed MR+AS 0 0.0 4 1.4 any new symptoms when again ambulatory Holter monitoring for MR+TR 1 20.0 5 1.9 24 hours was done. MS+BAV 1 100 1 0.4 MS+AR 1 25.0 4 1.4 STATISTICAL ANALYSIS MS+TR 1 100 1 0.4 For baseline comparison of patients, chi-square (χ2) test was used MS+AS 3 60 5 1.9 for descriptive variables. Quantitative variables were compared using the independent sample t-test. PS+TR 0 0.0 1 0.4 MS+AS+AR 0 0.0 3 1.1 Sample size estimation: AF is the dominant arrhythmia in the patients with VHD. By considering the prevalence of AF in VHD in MR +AS+AR 0 0.0 1 0.4 previous studies being 39% [3], we calculated the sample size (N) MR+AS+TR 1 100.0 1 0.4 using the following formula: MR+ AR+TR 0 0.0 1 0.4 • N= 4xPxQ/L2 MS+MR+AS 2 28.5 7 2.6 • Where P=prevalence of disease=40% MS+MR+TR 3 100.0 3 1.1 • Q=100-P=60% MS+MR+AR 2 25.0 8 2.9 • L=experimental error-15% of P=6% MS+MR+AS+ AR 9 100.00 9 3.4 • N=264.33=264(minimum sample required) MS+MR+AR+TR 1 50 2 0.7 100 268 RESULTS [Table/Fig-3]: Frequency of various valvular lesions in the study group and presence of atrial fibrillation with relation to different valvular lesions; (%) denotes There were 268 patients with mean age of 37±12 years in our study.
Load more

Recommended publications
  • WPW: WOLFF-PARKINSON-WHITE Syndrome
    WPW: WOLFF-PARKINSON-WHITE Syndrome What is Wolff-Parkinson-White Syndrome? Wolff-Parkinson-White Syndrome, or WPW, is named for three physicians who described a syndrome in 1930 in young people with episodes of heart racing and an abnormal pattern on their electrocardiogram (ECG or EKG). Over the next few decades, it was discovered that this ECG pattern and the heart racing was due to an extra electrical pathway in the heart. Thus, WPW is a syndrome associated with an abnormal heart rhythm, or “arrhythmia”. Most people with WPW do not have any other problems with their heart. Normally, the electrical impulses in the heart originate in the atria or top chambers of the heart and spread across the atria. The electrical impulses are then conducted to the ventricles (the pumping/bottom chambers of the heart) through a group of specialized cells called the atrioventricular node or AV node. This is usually the only electrical pathway between the atria and ventricles. In WPW, there is an additional pathway made up of a few extra cells left over from when the heart formed. The conduction of electricity through the heart causes the contractions which are the “heartbeat”. What is WPW Syndrome as opposed to a WPW ECG? A person has WPW Syndrome if they experience symptoms from abnormal conduction through the heart by the WPW pathway. Most commonly, the symptom is heart racing, or “palpitations”. The particular type of arrhythmia in WPW is called “supraventricular tachycardia” or SVT. “Tachycardia” means fast heart rate; “supraventricular” means the arrhythmia requires the cells above the ventricles to be part of the abnormal circuit.
    [Show full text]
  • Mitral Valve Prolapse, Arrhythmias, and Sudden Cardiac Death: the Role of Multimodality Imaging to Detect High-Risk Features
    diagnostics Review Mitral Valve Prolapse, Arrhythmias, and Sudden Cardiac Death: The Role of Multimodality Imaging to Detect High-Risk Features Anna Giulia Pavon 1,2,*, Pierre Monney 1,2,3 and Juerg Schwitter 1,2,3 1 Cardiac MR Center (CRMC), Lausanne University Hospital (CHUV), 1100 Lausanne, Switzerland; [email protected] (P.M.); [email protected] (J.S.) 2 Cardiovascular Department, Division of Cardiology, Lausanne University Hospital (CHUV), 1100 Lausanne, Switzerland 3 Faculty of Biology and Medicine, University of Lausanne (UniL), 1100 Lausanne, Switzerland * Correspondence: [email protected]; Tel.: +41-775-566-983 Abstract: Mitral valve prolapse (MVP) was first described in the 1960s, and it is usually a benign condition. However, a subtype of patients are known to have a higher incidence of ventricular arrhythmias and sudden cardiac death, the so called “arrhythmic MVP.” In recent years, several studies have been published to identify the most important clinical features to distinguish the benign form from the potentially lethal one in order to personalize patient’s treatment and follow-up. In this review, we specifically focused on red flags for increased arrhythmic risk to whom the cardiologist must be aware of while performing a cardiovascular imaging evaluation in patients with MVP. Keywords: mitral valve prolapse; arrhythmias; cardiovascular magnetic resonance Citation: Pavon, A.G.; Monney, P.; Schwitter, J. Mitral Valve Prolapse, Arrhythmias, and Sudden Cardiac Death: The Role of Multimodality 1. Mitral Valve and Arrhythmias: A Long Story Short Imaging to Detect High-Risk Features. In the recent years, the scientific community has begun to pay increasing attention Diagnostics 2021, 11, 683.
    [Show full text]
  • Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease
    Europace (2017) 0, 1–21 EHRA CONSENSUS DOCUMENT doi:10.1093/europace/eux240 Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardıaca y Electrofisiologıa (SOLEACE) Gregory Y. H. Lip1*, Jean Philippe Collet2, Raffaele de Caterina3, Laurent Fauchier4, Deirdre A. Lane5, Torben B. Larsen6, Francisco Marin7, Joao Morais8, Calambur Narasimhan9, Brian Olshansky10, Luc Pierard11, Tatjana Potpara12, Nizal Sarrafzadegan13, Karen Sliwa14, Gonzalo Varela15, Gemma Vilahur16, Thomas Weiss17, Giuseppe Boriani18 and Bianca Rocca19 Document Reviewers: Bulent Gorenek20 (Reviewer Coordinator), Irina Savelieva21, Christian Sticherling22, Gulmira Kudaiberdieva23, Tze-Fan Chao24, Francesco Violi25, Mohan Nair26, Leandro Zimerman27, Jonathan Piccini28, Robert Storey29, Sigrun Halvorsen30, Diana Gorog31, Andrea Rubboli32, Ashley Chin33 and Robert Scott-Millar34 * Corresponding author. Tel/fax: þ44 121 5075503. E-mail address: [email protected] Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author 2017. For permissions, please email: [email protected]. 2 G.Y.H. Lip 1Institute of Cardiovascular Sciences, University of Birmingham and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (Chair, representing EHRA); 2Sorbonne Universite´ Paris 6, ACTION Study Group, Institut De Cardiologie, Groupe Hoˆpital Pitie´-Salpetrie`re (APHP), INSERM UMRS 1166, Paris, France; 3Institute of Cardiology, ‘G.
    [Show full text]
  • Constrictive Pericarditis Causing Ventricular Tachycardia.Pdf
    EP CASE REPORT ....................................................................................................................................................... A visually striking calcific band causing monomorphic ventricular tachycardia as a first presentation of constrictive pericarditis Kian Sabzevari 1*, Eva Sammut2, and Palash Barman1 1Bristol Heart Institute, UH Bristol NHS Trust UK, UK; and 2Bristol Heart Institute, UH Bristol NHS Trust UK & University of Bristol, UK * Corresponding author. Tel: 447794900287; fax: 441173425926. E-mail address: [email protected] Introduction Constrictive pericarditis (CP) is a rare condition caused by thickening and stiffening of the pericar- dium manifesting in dia- stolic dysfunction and enhanced interventricu- lar dependence. In the developed world, most cases are idiopathic or are associated with pre- vious cardiac surgery or irradiation. Tuberculosis remains a leading cause in developing areas.1 Most commonly, CP presents with symptoms of heart failure and chest discomfort. Atrial arrhythmias have been described as a rare pre- sentation, but arrhyth- mias of ventricular origin have not been reported. Figure 1 (A) The 12 lead electrocardiogram during sustained ventricular tachycardia is shown; (B and C) Case report Different projections of three-dimensional reconstructions of cardiac computed tomography demonstrating a A 49-year-old man with a striking band of calcification around the annulus; (D) Carto 3DVR mapping—the left hand panel (i) demonstrates a background of diabetes, sinus beat with late potentials at the point of ablation in the coronary sinus, the right hand panel (iii) shows the hypertension, and hyper- pacemap with a 89% match to the clinical tachycardia [matching the morphology seen on 12 lead ECG (A)], and cholesterolaemia and a the middle panel (ii) displays the three-dimensional voltage map.
    [Show full text]
  • J Wave Syndromes
    Review Article http://dx.doi.org/10.4070/kcj.2016.46.5.601 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Korean Circulation Journal J Wave Syndromes: History and Current Controversies Tong Liu, MD1, Jifeng Zheng, MD2, and Gan-Xin Yan, MD3,4 1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, 2Department of cardiology, The Second Hospital of Jiaxing, Jiaxing, China, 3Lankenau Institute for Medical Research and Lankenau Medical Center, Wynnewood, Pennsylvania, USA, 4The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China The concept of J wave syndromes was first proposed in 2004 by Yan et al for a spectrum of electrocardiographic (ECG) manifestations of prominent J waves that are associated with a potential to predispose affected individuals to ventricular fibrillation (VF). Although the concept of J wave syndromes is widely used and accepted, there has been tremendous debate over the definition of J wave, its ionic and cellular basis and arrhythmogenic mechanism. In this review article, we attempted to discuss the history from which the concept of J wave syndromes (JWS) is evolved and current controversies in JWS. (Korean Circ J 2016;46(5):601-609) KEY WORDS: Brugada syndrome; Sudden cardiac death; Ventricular fibrillation. Introduction History of J wave and J wave syndromes The concept of J wave syndromes was first proposed in 2004 The J wave is a positive deflection seen at the end of the QRS by Yan et al.1) for a spectrum of electrocardiographic (ECG) complex; it may stand as a distinct “delta” wave following the QRS, manifestations of prominent J waves that are associated with a or be partially buried inside the QRS as QRS notching or slurring.
    [Show full text]
  • The Syndrome of Alternating Bradycardia and Tachycardia by D
    Br Heart J: first published as 10.1136/hrt.16.2.208 on 1 April 1954. Downloaded from THE SYNDROME OF ALTERNATING BRADYCARDIA AND TACHYCARDIA BY D. S. SHORT From the National Heart Hospita. Received September 15, 1953 Among the large number of patients suffering from syncopal attacks who attended the National Heart Hospital during a four-year period, there were four in whom examination revealed sinus bradycardia alternating with prolonged phases of auricular tachycardia. These patients presented a difficult problem in treatment. Each required at least one admission to hospital and in one case the symptoms were so intractable as to necessitate six admissions in five years. Two patients had mitral valve disease, one of them with left bundle branch block. One had aortic valve sclerosis while the fourth had no evidence of heart disease. THE HEART RATE The sinus rate usually lay between 30 and 50 a minute, a rate as slow as 22 a minute being observed in one patient (Table I). Sinus arrhythmia was noted in all four patients, wandering of TABLE I http://heart.bmj.com/ RATE IN SINus RHYTHM AND IN AURICULAR TACHYCARDIA Rate in Case Age Sex Associated Rate in auricular tachycardia heart disease sinus rhythm Auricular Venliicular 1 65 M Aortic valve sclerosis 28-48 220-250 60-120 2 47 F Mitral valve disease 35-75 180-130 90-180 on September 26, 2021 by guest. Protected copyright. 3 38 F Mitral valve disease 22-43 260 50-65 4 41 F None 35-45 270 110 the pacemaker in three, and periods of sinus standstill in two (Fig.
    [Show full text]
  • Unstable Angina with Tachycardia: Clinical and Therapeutic Implications
    Unstable angina with tachycardia: Clinical and therapeutic implications We prospectively evaluated 19 patients with prolonged chest pain not evolving to myocardiai infarction and accompanied with reversible ST-T changes and tachycardia (heart rate >lOO beats/min) in order to correlate heart rate reduction with ischemic electrocardiographic (ECG) changes. Fourteen patients (74%) received previous long-term combined treatment with nifedipine and nitrates. Continuous ECG monitoring was carried out until heart rate reduction and at least one of the following occurred: (1) relief of pain or (2) resolution of ischemic ECG changes. The study protocol consisted of carotid massage in three patients (IS%), intravenous propranolol in seven patients (37%), slow intravenous amiodarone infusion in two patients (lo%), and intravenous verapamil in four patients (21%) with atrial fibrillation. In three patients (16%) we observed a spontaneous heart rate reduction on admission. Patients responded with heart rate reduction from a mean of 126 + 10.4 beats/min to 64 k 7.5 beats/min (p < 0.005) and an ST segment shift of 4.3 k 2.13 mm to 0.89 k 0.74 mm (p < 0.005) within a mean interval of 13.2 + 12.7 minutes. Fifteen (79%) had complete response and the other four (21%) had partial relief of pain. A significant direct correlation was observed for heart rate reduction and ST segment deviation (depression or elevation) (f = 0.7527 and 0.8739, respectively). These patients represent a unique subgroup of unstable angina, in which the mechanism responsible for ischemia is excessive increase in heart rate. Conventional vasodilator therapy may be deleterious, and heart rate reduction Is mandatory.
    [Show full text]
  • Basic Arrhythmia Review Guide-Advanced
    BASIC ARRHYTHMIA REVIEW GUIDE ADVANCED The following study guide provides a review of information covered in the basic arrhythmia competency. Preparation with this guide will help to achieve success on the exam. Sample questions and websites are provided at the end of this guide. DESCRIPTION OF THE HEART The adult heart is a muscular organ weighing less than a pound and about the size of a clenched fist. It lies between the right and Left left lung in an area called the mediastinal cavity behind the sternum of the breast bone. Approximately two-thirds of the heart Atrium lies to the left of the sternum and one-third to the right of the sternum. Right HEART MUSCLES Atrium The heart is composed of three layers each with its own special function. The outermost layer is called the pericardium, essentially a sac around the heart. The middle and thickest layer of the heart is called the Left myocardium. This layer contains all the atrial and ventricular Ventricle muscle fibers needed for contraction as well as the blood supply Right and electrical conduction system. Ventricle The innermost layer of the heart is the endocardium and is composed of endothelium and connective tissue. Any disruption or injury to this endothelium can lead to infection, which in turn can cause valve damage, sepsis, or death. CHAMBERS A normal human heart contains four separate chambers: right atrium, left atrium, right ventricle, and left ventricle. The right and left sides of the heart are divided by a septum. The right atrium (RA) receives oxygen-poor (venous) blood from the body’s organs via the superior and inferior vena cava (SVC and IVC).
    [Show full text]
  • Percutaneous Mitral Valve Therapies: State of the Art in 2020 LA ACP Annual Meeting
    Percutaneous Mitral Valve Therapies: State of the Art in 2020 LA ACP Annual Meeting Steven R Bailey MD MSCAI, FACC, FAHA,FACP Professor and Chair, Department of Medicine Malcolm Feist Chair of Interventional Cardiology LSU Health Shreveport Professor Emeritus, UH Health San Antonio [email protected] SRB March 2020 Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company • Grant/Research Support • None • Consulting Fees/Honoraria • BSCI, Abbot DSMB • Intellectual Property Rights • UTHSCSA • Other Financial Benefit • CCI Editor In Chief SRB March 2020 The 30,000 Ft View Maria SRB March 2020 SRB March 2020 Mitral Stenosis • The most common etiology of MS is rheumatic fever, with a latency of approximately 10 to 20 years after the initial streptococcal infection. Symptoms usually appear in adulthood • Other etiologies are rare but include: congenital MS radiation exposure atrial myxoma mucopolysaccharidoses • MS secondary to calcific annular disease is increasingly seen in elderly patients, and in patients with advanced chronic kidney disease. SRB March 2020 Mitral Stenosis • Mitral stenosis most commonly results from rheumatic heart disease fusion of the valve leaflet cusps at the commissures thickening and shortening of the chordae calcium deposition within the valve leaflets • Characteristic “fish-mouth” or “hockey stick” appearance on the echocardiogram (depending on view) SRB March 2020 Mitral Stenosis: Natural History • The severity of symptoms depends primarily on the degree of stenosis. • Symptoms often go unrecognized by patient and physician until significant shortness of breath, hemoptysis, or atrial fibrillation develops.
    [Show full text]
  • How to Define Valvular Atrial Fibrillation?
    Archives of Cardiovascular Disease (2015) 108, 530—539 Available online at ScienceDirect www.sciencedirect.com REVIEW How to define valvular atrial fibrillation? Comment définir la fibrillation atriale valvulaire ? ∗ Laurent Fauchier , Raphael Philippart, Nicolas Clementy, Thierry Bourguignon, Denis Angoulvant, Fabrice Ivanes, Dominique Babuty, Anne Bernard Service de cardiologie, faculté de médecine, université Franc¸ois-Rabelais, CHU Trousseau, Tours, France Received 3 June 2015; accepted 8 June 2015 Available online 14 July 2015 KEYWORDS Summary Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials compar- Atrial fibrillation; ing vitamin K antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in Valve disease; AF were performed among patients with so-called ‘‘non-valvular’’ AF. The distinction between Stroke ‘‘valvular’’ and ‘‘non-valvular’’ AF remains a matter of debate. Currently, ‘‘valvular AF’’ refers to patients with mitral stenosis or artificial heart valves (and valve repair in North American guidelines only), and should be treated with VKAs. Valvular heart diseases, such as mitral regur- gitation, aortic stenosis (AS) and aortic insufficiency, do not result in conditions of low flow in the left atrium, and do not apparently increase the risk of thromboembolism brought by AF. Post-hoc analyses suggest that these conditions probably do not make the thromboembolic risk less responsive to NOACs compared with most forms of ‘‘non-valvular’’ AF. The pathogenesis of thrombosis is probably different for blood coming into contact with a mechanical prosthetic valve compared with what occurs in most other forms of AF. This may explain the results of the only trial performed with a NOAC in patients with a mechanical prosthetic valve (only a few of whom had AF), where warfarin was more effective and safer than dabigatran.
    [Show full text]
  • Tachycardia (Fast Heart Rate)
    Tachycardia (fast heart rate) Working together to improve the diagnosis, treatment and quality of life for all those aff ected by arrhythmias www.heartrhythmalliance.org Registered Charity No. 1107496 Glossary Atrium Top chambers of the heart that receive Contents blood from the body and from the lungs. The right atrium is where the heart’s natural pacemaker (sino The normal electrical atrial node) can be found system of the heart Arrhythmia An abnormal heart rhythm What are arrhythmias? Bradycardia A slow heart rate, normally less than 60 beats per minute How do I know what arrhythmia I have? Cardiac Arrest the abrupt loss of heart function, breathing and consciousness Types of arrhythmia Cardioversion a procedure used to return an abnormal What treatments are heartbeat to a normal rhythm available to me? Defi brillation a treatment for life-threatening cardiac arrhythmias. A defibrillator delivers a dose of electric current to the heart Important information This booklet is intended for use by people who wish to understand more about Tachycardia. The information within this booklet comes from research and previous patients’ experiences. The booklet off ers an explanation of Tachycardia and how it is treated. This booklet should be used in addition to the information given to you by doctors, nurses and physiologists. If you have any questions about any of the information given in this booklet, please ask your nurse, doctor or cardiac physiologist. 2 Heart attack A medical emergency in which the blood supply to the heart is blocked, causing serious damage or even death of heart muscle Tachycardia Fast heart rate, more than 100 beats per minute Ventricles The two lower chambers of the heart.
    [Show full text]
  • Echo in Asymptomatic Mitral and Aortic Regurgitation
    2017 ASE Florida | Orlando, FL October 9, 2017 | 10:40 – 11:00 PM | 20 min | Grand Harbor Ballroom South Echo in Asymptomatic Mitral and Aortic Regurgitation Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology | Echo Lab Associate Professor of Medicine Disclosures Speakers Bureau (Philips, Medtronic) Advisory Board (Siemens) Regurgitation Axioms ▪Typically, regurgitation is NOT symptomatic unless severe ▪The opposite is not true: Severe regurgitation may be asymptomatic ▪ Chronic regurgitation leads to chamber dilatation on either side of the regurgitant valve Regurgitation Discovery ▪ Regurgitation as a anatomic entity was recognized in the 17th century ▪ Regurgitation was first clinically diagnosed by auscultation in the 19th century, well before the advent of echocardiography First Use of Regurgitation Term in English 1683 W. Charleton Three Anat. Lect. i. 18 Those [valves] that are placed in the inlet and outlet of the left Ventricle, to obviate the regurgitation of the bloud into the arteria venosa, and out of the aorta into the left Ventricle. Walter Charleton (1619 – 1707) English Physician Heart Murmur OXFORD ENGLISH DICTIONARY DEFINITION ▪ Any of various auscultatory sounds ▪ Adventitious sounds of cardiac or vascular origin [that is, separate from standard heart sounds: S1, S2, S3, S4] ▪ Sometimes of no significance ▪ But sometimes caused by valvular lesions of the heart or other diseases of the Στῆθος : Stēthos = chest circulatory system René Laënnec Stethoscope (1781 – 1826) (‘Chest examiner’) French Physician Hollow wooden cylinder Inventor of stethoscope in 1816 Laënnec Performing Auscultation Painted by Robert Alan Thom (1915 – 1979), American illustrator Commissioned by Parke, Davis & Co. 1816 1832 René Laënnec, James Hope French physician British physician Invents MONAURAL stethoscope separates MS from MR murmur 1852 1862 George Cammann Austin Flint Sr.
    [Show full text]